

SPRING 2023

NeuroNEXT

from the Departments of Neurological Sciences & Neurosurgery

Spring is here and with it comes new opportunities in the neurosciences departments.

We welcome a couple of new faculty members, spotlight research in the lab of Anna Dunaevsky, PhD, and clinical trials happening in the newly renovated Neurosciences Clinical Research Center on the third floor of Clarkson Doctors North. The center is run by the Department of Neurological Sciences (DONS) longtime professor Dan Murman, MD, MS.

Neurosurgery has been busy. We have a new clinical trial with Jamie Wilson, MD, community outreach efforts led by Nicholas Borg, MD, and a new grant for Steve Gliske, PhD.

We also provide an update on last year's Congressional Neuroscience Caucus, upcoming events and an inspiring story about a brain aneurysm fundraiser. We hope you enjoy this spring edition of our NeuroNEXT Newsletter!



Matthew Rizzo, MD,
FAAN, FANA
*Frances & Edgar Reynolds Professor
and Chair, Department of Neurological
Sciences*



Aviva Abosch, MD, PhD
*Nancy A. Keegan & Donald R.
Voelte, Jr. Professor and Chair,
Department of Neurosurgery*



Howard Fox, MD, PhD
*Senior Associate Dean, Research &
Development, College of Medicine
Professor, Department of
Neurological Sciences*

In This Issue

- 1 Introduction
- 2 New Faculty
- 3 FRAXA Grant
- 4 Updates from
Neurosurgery
- 5 Neuro-CRC Expanding
and Enhancing Clinical
Trials Research
- 7 2023 Research Summit
- 8 Congressional
Neuroscience Caucus
- 9 MS Program Poster
Presentations
- 10 Brain Aneurysm
Fundraiser
- 11 Ukraine Efforts
MS Strong
Community Race
How to Support DONS

Welcome! New Faculty

Neurological Sciences



Lyubov Butsyak, APRN in the DONS

Hometown: Lviv, Ukraine

Three things people may not know about me:

- I speak five languages: Ukrainian, Russian, Polish, German and English.
- My first career was in fine arts: clothing design and embroidery. I graduated from the College of Fine Arts, Lviv, Ukraine. I taught art before moving to the U.S.
- I love a good adventure, traveling and being outdoors! Skiing, hiking, canoeing, swimming and exploring beaches and mountains. I have visited Australia, Singapore, Mexico and several other European and Asian countries.

Neurosurgery




Mithun Sattur, MD, joined UNMC's Department of Neurosurgery and the Division of Vascular Neurosurgery in April 2023

A native of India, Dr. Sattur completed medical school at Karnataka Institute of Medical Sciences, followed by neurosurgery residency at the National Institute of Mental Health and Neurosciences in India. Dr. Sattur then came to the US, completing a Neurosurgical Oncology Fellowship at the Rose Ella Burkhard Brain Tumor Institute of the Cleveland Clinic, followed by fellowships in endovascular, cerebrovascular and skull base surgery at the Mayo Clinic.

After fellowship training, he joined the Neurosurgery Department at the Medical University of South Carolina, where he completed a second neurosurgery residency. Dr. Sattur's clinical and research interests focus on the treatment of complex vascular disorders and skull base tumors.

Dunaevsky Lab Investigates the Role of Astrocytes in ASD/FXS with support from a FRAXA Grant

by Lara Bergdolt, PhD, Postdoctoral Research Associate in the Dunaevsky Lab



Lara Bergdolt, PhD, and Anna Dunaevsky, PhD, study ASD/FXS

The neural mechanisms underlying autism spectrum disorder (ASD) are not completely understood. Many people with ASD and/or fragile X syndrome (FXS) experience sensory hypersensitivity to tactile, auditory and/or visual stimuli, which may contribute to other symptoms, making it important to understand the underlying mechanisms to further research toward treatment.

In the Dunaevsky lab, we explore these mechanisms by using a mouse model of FXS, the most common inherited form of ASD, which is caused by loss of expression of the fragile X messenger ribonucleoprotein 1 (Fmr1) gene.

Our lab and others have shown that Fmr1 knockout (KO) mice exhibit tactile and auditory hypersensitivity. We are particularly interested to learn how astrocytes, a type of non-neuronal brain cell, contribute to these phenotypes, as most research to date has focused on neuronal impairments in the absence of Fmr1.

To investigate the role of astrocytes, we are using Fmr1 conditional KO (cKO) mice, which have astrocyte-specific deletion of Fmr1. We found that cKO mice exhibit both tactile

and auditory hypersensitivity, indicating that astrocytes contribute to these phenotypes.

Altered astrocytic calcium signaling appears to be a mechanism underlying auditory hypersensitivity. Calcium signaling is critical for normal astrocyte function, and we discovered that astrocytes lacking Fmr1 exhibit elevated calcium signaling. We found that genetically reducing astrocytic calcium signaling reduces auditory hypersensitivity

in Fmr1 cKO mice. This finding provides an attractive target with therapeutic potential, and we have recently started working to develop an antagonist that will specifically target astrocytic calcium signaling.

The FRAXA Research Foundation awarded us a grant to continue this work, which will involve drug development and identification of other potential therapeutic targets for fragile X syndrome.

A knockout mouse is a laboratory mouse in which researchers have inactivated, or “knocked out,” an existing gene by replacing it or disrupting it with an artificial piece of DNA. Created in 1989, it is a standard research tool in labs.

National Human Genome Research Institute

Updates from the Department of Neurosurgery

CASPER Trial



Jamie Wilson, MD

Jamie Wilson, MD, and the neurosurgery research team have recently enrolled their first subject in the CASPER trial.

The Canadian-American Spinal Cord and Perfusion Pressure and Biomarker Study is an international multi-center trial focused on improving outcomes for patients with traumatic spinal cord injuries.

The study uses augmentation of drainage of cerebrospinal fluid (CSF) to alter the intrathecal pressure when measured against the mean arterial blood pressure to produce changes in the 'Spinal Cord Perfusion Pressure' (SCPP). This is analogous to 'intracranial pressure' augmentation, which has been used historically for decades in the treatment of traumatic brain injuries. Initial studies have shown patients with a higher SCPP after spinal cord injury have a much higher rate of conversion to better clinical outcomes compared to patients with a lower SCPP. The study hopes to prove real-time augmentation of SCPP can produce similar outcomes. CSF is also collected at frequent intervals up to seven days after injury to be stored in the international spinal cord injury biobank located in Vancouver and governed by the University of British Columbia (PI: Professor Brian Kwon). Dr. Wilson and the team continue to actively recruit subjects and look forward to playing a part in changing the lives of future spinal cord injured patients.

Outreach Efforts



Nicolas Borg, MD

Nicholas Borg, MD, visited the Bennington Fire Station on January 9 for a talk on stroke care at UNMC.

The session was used as a forum to discuss how to identify patients with symptoms of a stroke and specifically selecting those at risk of major ischemic stroke to be routed directly to a Comprehensive Stroke


Center. Along with Nichole Cooks, stroke coordinator for Nebraska Medicine, Dr. Borg discussed how these patients are cared for after arrival. He specifically mentioned how pre-alerting the stroke team allows us to greet them at the door for a 'stroke stop,' bypassing the emergency department and going straight to CT to initiate treatment as soon as possible and salvage as much tissue as possible.

The session was attended by approximately 50 emergency services providers, ranging in experience from the fire chief to novice volunteers on their first day on the job! Dr. Borg had great things to say about the experience, "It was an enjoyable opportunity to ask each other questions and better understand how we can work together to improve the delivery of time-critical patient care."

Dr. Steve Gliske receives Great Plains IDeA-CTR Transfer Grant

The \$50,000 in funds will be used to validate a prototype neural monitor for infants in the ICU, extending upon work currently funded by the NHLBI Catalyze Program.





Neuro-CRC is Expanding and Enhancing Clinical Trial Research

The Neurological Sciences Clinical Research Center (Neuro-CRC), established in 2019. Located in the Clarkson Doctors North Tower, suite 363. The center provides departmental staff, clinical research coordinators and facilities research assessment close to the Neurological Science Clinics.

The Neuro-CRC facilitates clinical trial research of new therapeutics for neurologic disorders by providing departmental staff, clinical research coordinators and facilities for research assessments close to the Neurological Sciences Clinics. The Neuro-CRC has rooms for performing cognitive testing, neurologic exams, vital signs, ECG, and blood draws and a lab for specimen processing. Dan Murman, MD, MS, serves as the medical director of the Neuro-CRC. Deb Heimes is the administrative lead and coordinates four clinical research coordinators (Nick Miller, Haley Kampschnieder, Katelyn Hiltz, RN, and Rachel Harper, RN). Currently, the Neuro-

CRC is coordinating 22 active trials, and an additional eight trials are in start-up or under review. For more information about the Neuro-CRC, you can contact Deb Heimes by email at deb.heimes@unmc.edu.

Brigette Vaughan, MSN, NP, joined the Department of Neurological Sciences recently and will lead efforts to increase investigator-initiated clinical trials in the department. In 2023, Ren Haasch joined the Neuro-CRC as a research assistant, and Jeanne Welte, RN, will join as a clinical research nurse coordinator. Current Neuro-CRC trials include studies for patients with Alzheimer's disease (AD), amyotrophic

lateral sclerosis (ALS), epilepsy, movement disorders, multiple sclerosis and stroke. The following is a summary of these trials.

Alzheimer's Disease and Related Disorders (ADRD) Trials

Dr. Murman is the site principal investigator (PI) for ADRD trials; Nick Miller and Haley Kampschnieder are the study coordinators. UNMC has been a trial site for the Anti-Amyloid Immunotherapy in Asymptomatic Alzheimer's (**A4** Study, IRB # 038-14) since 2015. This is a five-year secondary prevention trial investigating

cont. pg. 6

whether solanezumab can delay the onset of symptoms of AD in asymptomatic older adults who have increase brain amyloid detected on an amyloid PET scan. We have also participated in the companion observational study of similar subjects who had a normal amyloid PET scan (Longitudinal Evaluation of Amyloid Risk and Neurodegeneration — **LEARN study**, IRB # 666-15). These studies are supported by the National Institutes of Health (NIH), industry and the Alzheimer's Association and are coordinated by the Alzheimer's Clinical Trial Consortium. Results from these trials are expected in the Spring 2023.

We currently are recruiting for a trial of another anti-amyloid immunotherapy (aducanumab) in subjects with prodromal to mild Alzheimer's disease, called the **Envision Study** (IRB # 477-22). We collaborated with Aviva Abosch MD, PhD, chair of UNMC's Department of Neurosurgery, on a trial of deep brain stimulation of the fornix in subjects with mild AD (**ADvance II Study**, IRB # 026-20), which recently ended.

We are in the start-up phase of two new studies, one on an oral medication (buntanetap) for subjects with mild to moderate AD and the other a trial of neflamapimod in subjects with dementia with lewy bodies.

For more information about ADRD trials at UNMC, you can send an email to adtrials@unmc.edu.

ALS and Neuromuscular Disorders Trials

Americo Fernandes, MD, is leading ALS clinical trials at UNMC, and Rachel Harper, RN, has been the lead study coordinator. UNMC is part of the **Healy ALS Platform Trial** being led by investigators at Massachusetts General Hospital. This platform trial has built a network of trial sites and the infrastructure to efficiently perform a series of trials of new medications for ALS, with support from the NIH, industry and philanthropy. We have enrolled subjects into four regiments (i.e., four different medications), and a fifth regiment is

now enrolling (IRB # 347-20).

Dr. Fernandes is also enrolling ALS subjects into a phase 2 trial of an oral medication (PTC857) for subjects with milder ALS symptoms (**Cardinal Trial**, IRB # 597-22).

UNMC is participating in a natural history and biomarker study of a related disorder, **Primary Lateral Sclerosis** (IRB # 367-21). Also, a new study for subjects with inclusion body myositis will investigate the effectiveness of a monoclonal antibody (ABC008) in treating this disease. Ezequiel Piccione, MD, (site PI) will lead this study, which is in the start-up phase; and Katelyn Hilz, RN, will be the lead study coordinator.

Epilepsy Studies

Olga Taraschenko, MD, PhD, is conducting a natural history and biomarker study of patients with New Onset Refractory Status Epilepticus (**NORSE**, IRB # 439-19) and a phase 4, post-approval study of the outcomes of patients with refractory epilepsy who were treated with **Responsive Neurostimulation** (RNS, IRB # 689-17) epilepsy surgery. Dr. Taraschenko is also starting recruitment for an investigator-initiated study using in vivo monitoring of neurogenesis in patients who have had encephalitis compared to a control group (IRB # 562-22).

Movement Disorder Trials

Amy Hellman, MD, is the site PI for a Huntington's disease (HD) natural history study, which is enrolling subjects (**Enroll HD**, IRB # 338-16) and a clinical trial of valbenazine for the treatment of chorea in subjects with HD (**Kinect HD**, IRB # 830-19). Mara Seier, MD, is the site PI for a phase 2 trial investigating a monoclonal antibody that targets toxic forms of alpha synuclein in subjects with Multiple System Atrophy (**Amulent MSA Trial**, IRB # 833-21). Erin Smith, MD, is the site PI for a study of Botox in the treatment of Essential Tremor (**Merz ET Trial**, IRB # 399-21).

Multiple Sclerosis Trials

Rana Zabad, MD, directs UNMC's involvement in clinical trials for patients with multiple sclerosis (MS), and Katelyn Hilz,

RN, is the lead study coordinator for MS trials. Neil Jouvenat, PA, is actively involved in assessments of MS subjects enrolled in MS clinical trials. UNMC is involved in two ongoing studies of novel immunotherapies for MS, including an extension study of ocrelizumab in relapsing and remitting MS (**OLERO Trial**, IRB # 487-22) and a trial of a BTK inhibitor (SAR442168) in subjects with primary progressive MS (**Perseus Trial**, IRB # 896-20). Dr. Zabad and the MS team are participating in a trial comparing Traditional vs. Early Aggressive Therapy for MS (**TREAT MS Trial**, IRB # 196-20). In addition, we have recently begun participation in a national study of treatment outcomes in patients with MS (i.e., the MS Leadership and Innovation Network (**MS LINK**) **Outcomes Study**, IRB # 435-22).

Stroke Trials

Pierre Fayad, MD, has led stroke trials at UNMC for many years; he will be joined by Marco Gonzales, MD, in serving as site-PI on some stroke clinical trials going forward. Study coordination has been provided by nurse coordinators through the UNMC-CRC, including the addition of Jeanne Welte, RN, to the Neuro-CRC staff, who will take over study coordination on new stroke trials.

UNMC has been a clinical trial site for many NIH StrokeNET trials. NIH StrokeNET is a multicenter, cooperative, clinical trial group supported by the NIH Neurological Disorders and Stroke (NINDS). Currently, UNMC is involved in four NIH StrokeNET trials described here: **ASPIRE** (IRB # 462-20) is investigating the potential role of anticoagulation to prevent ischemic stroke in patients who have had an intracerebral hemorrhage. **Sleep Smart** (IRB # 706-19) is investigating the value of CPAP treatment of obstructive sleep apnea in those with stroke and sleep apnea. **ARCADIA** (IRB # 740-17) is investigating atrial cardiomyopathy and antithrombotic drugs in prevention (of recurrent stroke) after cryptogenic stroke. Saturn (IRB # 163-20) is investigating statin use in intracerebral hemorrhage patients. Three other stroke trials are in start-up or under review.

2023 Research Summit

The UNMC College of Medicine, UNMC Vice Chancellor for Research Office, and the Great Plains IDeA-Clinical and Translational Research (CTR) Network hosted the **2023 Joint Research Summit: Innovative Hospital-University Partnerships to Enhance Clinical and Translational Research** on March 13 at UNMC.

The purpose was to weigh best practices and OKRs (Objective and Key Results) for collaborative biomedical research across hospital and university partners, directly in line with our institutional goals.

We focused on innovative hospital-university partnerships to enhance CTR. We provided frameworks for how other institutions work, as well as opportunities for internal discussion around topics such as funds flow, research conducive IT and integrating diversity, equity and inclusion (DEI) into CTR.

The event featured UNMC Chancellor Jeff Gold, MD, Nebraska Medicine CEO Jim Linder, MD, UNMC College of Medicine Dean Bradley Britigan, MD, and scientific experts from aligned institutions. Dr. Michele McGuirl of the NIH IDeA programs was in attendance as innovative hospital-university partnerships are central to the overall NIH mission success.



Invited guests included Nebraska Medicine leadership, UNMC collegiate deans, department chairs and scientific leaders, and members from the Office of the Vice Chancellor for Research at UNMC, the University of Nebraska-Lincoln and the University of Nebraska at Omaha.

Congressional Neuroscience Caucus

by Matt Rizzo, MD

On Wednesday September 21, 2022, the American Brain Coalition (ABC), chaired by Dr. Matt Rizzo and the American College of Neuropharmacology hosted a Congressional briefing on potential use of psychedelics in treatment of psychiatric diseases.

Congressman Earl Blumenauer (D-OR) emphasized the importance of finding treatments such as psychedelics for brain injuries and disorders and urged the Drug Enforcement Agency (DEA) to allow terminally ill medical patients to have access to psilocybin.

Nora Volkow, MD, director of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH) defined psychedelics as “mind-altering drugs that influence physiological, cognitive, and emotional states,” which can be categorized as: classic hallucinogenic drugs; dissociative drugs; and others. Dr. Volkow addressed misinformation on the long-term impacts of psychedelics, including that they do not result in dementia and are generally not addictive, with ketamine being an exception. She

highlighted the high scientific and public interest in this research while noting the lack of patient diversity as well as small sample sizes in psychedelic studies. Dr. Volkow outlined mechanisms and emphasized the current gaps, challenges, and opportunities for conducting and translating research on psychedelic drugs, including translating findings from research trials into clinical practice. She highlighted that while emerging research indicates a potential benefit of methylenedioxymethamphetamine (MDMA) and psilocybin as treatments for post-traumatic stress disorder (PTSD), depression and cancer-related anxiety, evidence does not yet support using these drugs outside of a research setting. She also emphasized the critical importance of access to psychedelic drugs for research purposes.

Mr. Marcus Capone, former Navy SEAL, founder and chair of VETS Inc., operating partner at Red Cell Partners, and founder of Tara Mind, shared his personal experiences with the effects of psychedelics in the treatment of psychiatric diseases. Mr. Capone mentioned his experiences with options available to him after his service in Iraq and Afghanistan including mood stabilizers, anti-depressants, five brain treatment centers and other evidence-based modalities, which were not effective.

Mark Rasenick, PhD, vice chair of the ABC and distinguished professor of physiology, biophysics and psychiatry at the University of Illinois, Chicago, moderated this discussion. UNMC is currently engaged in a clinical trial on effects of cannabidiol on PTSD.




T. Scott Diesing, MD, elected Vice Chair of the AAN Neurohospitalist Section

Multiple Sclerosis Program 2023 Poster Presentations

Members of the Multiple Sclerosis Program, led by Rana Zabad, MD, presented at two national meetings this spring.

Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum
February 2023 | San Diego, California

- **Acute pancreatitis in a patient with MOG antibody-associated diseases treated with ocrelizumab: a case report and literature review**
Authors: Shirani A., Roat J., Jayagopal LA., Dafney N., Stuve O., Cross A.
- **Nitinol in Medical Devices and Delayed Type Hypersensitivity**
Authors: Zabad R.K., Thedinger B., Solis K., Venegas C., Dennis E., Piccione E., Westerhuis B., Jayagopal LA.
- **A Propos of an Adolescent with Familial Hemophagocytic Lymphohistiocytosis Presenting as CLIPPERS**
Authors: Zhou D.J., Darwish M., Ford J., Patel S., Koh S., Rathore G., Zabad R.K.
- **Posterior Spinal Cord Infarct: Thinking Outside the Box**
Authors: Solis K., Zabad R.K.



Afsaneh Shirani, MD, MSCI, presents poster at the ACTRIMS forum in San Diego

American Academy of Neurology Annual Meeting
April 2023 | Boston, Massachusetts

- **Nitinol in Medical Devices: Not so Innocuous**
Authors: Zabad R.K., Thedinger B., Solis K., Venegas C., Dennis E., Piccione E., Westerhuis B., Jayagopal L.A.
- **Pediatric Clippers? Think Again!**
Authors: Zhou D., Darwish M., Ford J., Patel S., Koh S., Rathore G., Zabad R.K.

Brain aneurysm fundraiser raises awareness and celebrates life

by Nebraska Medicine

Ranae Upton still remembers that terrifying day 15 years ago when she learned her husband, Tim, was lying in a field unconscious after experiencing a brain aneurysm while hunting with his father.

After arriving at the hospital, a team of doctors, nurses and a chaplain met her in the emergency room and took her back to his room.

“That’s when I knew life had changed,” recalls Ranae. Tim was only 33 years old. He fell unconscious when a blood vessel in his brain ruptured and then closed up.

Tim’s aneurysm was repaired two days later by surgery performed by Nebraska Medicine neurosurgeon William Thorell, MD. Aside from a few slight deficits, today, Tim is doing very well and continues to run his construction company.

Tim was very fortunate. Ruptured brain aneurysms are fatal in about 50% of cases.

The Upton family celebrates Tim’s life and those of other survivors at the annual A Sharp Race Toward Brain Aneurysm event. This fundraiser supports the Brain Aneurysm Foundation, the Nebraska Medicine Anita Sharp Brain Aneurysm Fund, and the Nebraska Medicine Brain Aneurysm Patient and Research Fund.

The event was started in 2013 by the Anita Sharp family and a nurse in the Nebraska Medical Center Critical Care Unit to raise awareness of brain aneurysms. Sharp was a Nebraska Medical Center patient who survived an aneurysm repaired by Dr. Thorell.



Ranae took over as race director of the event in 2019.

“It’s become such a special event for our family and many others who come together in gratitude, share our experiences with each other and give thanks to the ICU staff,” says Ranae.

“The event also brings survivors and survivor caregivers together, providing them with support, sounding boards and lifelong friendships,” says Nichole Cooks, BSN, RN, Nebraska Medicine Stroke Program coordinator. “We also invite them to participate in our stroke support group co-managed with Madonna Rehabilitation Hospital, where education, support and sharing are provided for aneurysm patients and their families.”

Half the money raised at the event

supports the Brain Aneurysm Foundation. The other half supports the education of neurology intensive care nurses at Nebraska Medical Center, the hospital’s support group, and patient assistance for brain aneurysm patients and their families. These families require basic needs such as lodging, meals, clean clothing, hygiene items, gas cards and transportation. The fund was recently expanded to include support for University of Nebraska Medical Center aneurysm research.

“It’s wonderful that a group of families and survivors have come together to raise funds for other families in need,” says Emily Tiensvold, University of Nebraska Foundation senior director of development. “And they continue to give back to the Neuro ICU team who tirelessly care for families day and night.”

The NU Foundation offers numerous ways you can help support the mission of Nebraska Medicine and our employees. Visit nufoundation.org/give/Nebraska-Medicine to learn more.

Ukrainian Efforts Continue

by Olga Taraschenko, MD, PhD

Since the start of this initiative in March 2022, we have sent more than 50 pallets of medical supplies to the hospitals in Dnipro, Kherson, Mykolaiv, Kharkiv and Kyiv. The doctors are extremely grateful. We have also shipped tactical medicine items such as tourniquets, hemostatic gaze, etc. to the dozens of field medical units in Donbass and other Eastern regions. We know firsthand that it has saved lives and allowed the wounded to be transported to the hospitals.

If you wish to donate, please visit <https://gofund.me/909edbca>



Hospitals in Kherson and Mykolaiv received the latest shipment at the end of February

Multiple Sclerosis Strong Community Race Event

UNMC and Nebraska Medicine Multiple Sclerosis Clinic's MAHA Program will host a fun run and 5K with proceeds being used to directly empower people living with multiple sclerosis and other demyelinating diseases with disability in our community. This will be a fun day for the whole family, and we encourage those who are able to come out and enjoy the event with us!

Saturday, May 20, 2023

9 a.m. – 3 p.m.

Aksarben Village – Stinson Park
2285 S 67th St., Omaha, Nebraska

Registration: Fun Run & 5K (\$30) or 10K (\$40)
Registration includes Race Entry, Race Bib and Official Race Shirt.

Other Activities: Food trucks, DJ and Family-fun activities.



To register visit: <https://www.nebraskamarathon.org/ms-strong/>

Ways to Support the Neurosciences

Mental and neurological disorders have never been more prevalent. Life-changing disorders including epilepsy, stroke, Alzheimer's disease, Parkinson's disease, multiple sclerosis and brain injuries touch the lives of far too many.

We are committed to providing the best treatment available today, as well as pioneering new therapies for the future. Our team of internationally recognized physicians and researchers is dedicated to saving lives, relieving suffering and reducing the terrible impact of neurological disease on our patients, families and community.

Private donations play a critical role in advancing our state-of-the-art research, treatment, education,

and patient care programs. Whether you would like to support patient care, research in a particular disease area, or the education of our next generation of doctors and scientists, your charitable gift can be directed to a project or topic that is most meaningful to you.

Gifts can be directed to any fund of your choice, or you can email to Emily Tiensvold with the University of Nebraska Foundation about a donation to your area of special interest at emily.tiensvold@nufoundation.org.



Emily Tiensvold



University of Nebraska Medical Center
Department of Neurological Sciences
988440 Nebraska Medical Center
Omaha, NE 68198-8440

If you have any news or upcoming events that you would like featured in the next edition of the *NeuroNExT UNMC* newsletter, please send the information to sallie.weathers@unmc.edu

Follow us at

Department of Neurological Sciences

 unmc.edu/neurologicalsciences

 [@UNMC_neurology](https://twitter.com/UNMC_neurology)

Department of Neurosurgery

 unmc.edu/neurosurgery

 [@UNMC_neurosurg](https://twitter.com/UNMC_neurosurg)

UNIVERSITY OF
Nebraska
Medical Center

